Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer — NEJM

Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non–small-cell lung cancer. We evaluated the feasibility of large-scale sc

www.nejm.org